| CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, the company is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, it engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. The company has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| TOMSICEK MICHAEL JOHN | Chief Financial Officer | Aug 03 | Option Exercise | 17.75 | 12,000 | 213,000 | 12,410 | Aug 05 04:20 PM | | TOMSICEK MICHAEL JOHN | Chief Financial Officer | Aug 03 | Sale | 86.74 | 12,000 | 1,040,919 | 410 | Aug 05 04:20 PM | | Novak Rodger | President | Jul 07 | Option Exercise | 11.28 | 25,000 | 281,907 | 673,007 | Jul 09 04:00 PM | | Novak Rodger | President | Jul 07 | Sale | 90.00 | 25,000 | 2,250,000 | 648,007 | Jul 09 04:00 PM | | Bolzon Bradley J PhD | Director | Jul 06 | Sale | 82.39 | 20,000 | 1,647,730 | 554,190 | Jul 08 04:00 PM | | Novak Rodger | President | Jul 01 | Sale | 80.00 | 50,000 | 4,000,000 | 648,007 | Jul 06 04:14 PM | | Klein Lawrence Otto | CBO & COO | Jun 25 | Option Exercise | 12.57 | 4,912 | 61,744 | 24,912 | Jun 26 04:33 PM | | Klein Lawrence Otto | CBO & COO | Jun 25 | Sale | 75.18 | 4,912 | 369,272 | 20,000 | Jun 26 04:33 PM | | Klein Lawrence Otto | CBO & COO | Jun 24 | Option Exercise | 8.58 | 65,088 | 558,707 | 58,666 | Jun 26 04:33 PM | | Klein Lawrence Otto | CBO & COO | Jun 24 | Sale | 75.93 | 65,088 | 4,942,292 | 20,000 | Jun 26 04:33 PM | | Ho Tony W | Executive VP, Head of R&D | Jun 23 | Sale | 75.20 | 6,929 | 521,061 | 33,747 | Jun 24 05:58 PM | | Novak Rodger | President | Jun 23 | Sale | 75.00 | 50,000 | 3,750,000 | 698,007 | Jun 25 04:28 PM | | Bolzon Bradley J PhD | Director | Jun 23 | Sale | 75.35 | 10,000 | 753,453 | 574,190 | Jun 24 07:02 PM | | Bolzon Bradley J PhD | Director | Jun 22 | Sale | 72.51 | 10,000 | 725,069 | 584,190 | Jun 24 07:02 PM | | Ho Tony W | Executive VP, Head of R&D | Jun 22 | Sale | 70.14 | 229 | 16,062 | 40,676 | Jun 24 05:58 PM | | Kulkarni Samarth | Chief Executive Officer | Jun 01 | Option Exercise | 1.81 | 17,275 | 31,268 | 188,801 | Jun 03 05:32 PM | | Kulkarni Samarth | Chief Executive Officer | Jun 01 | Sale | 64.68 | 17,275 | 1,117,266 | 171,526 | Jun 03 05:32 PM | | Ho Tony W | Executive VP, Head of R&D | May 26 | Sale | 70.14 | 6,100 | 427,854 | 40,905 | May 27 04:32 PM | | Novak Rodger | President | May 26 | Sale | 70.27 | 36,616 | 2,573,006 | 748,007 | May 27 04:34 PM | | Novak Rodger | President | May 22 | Sale | 70.01 | 13,384 | 937,014 | 784,623 | May 27 04:34 PM | | Ho Tony W | Executive VP, Head of R&D | May 22 | Sale | 70.05 | 600 | 42,030 | 47,005 | May 27 04:32 PM | | Kulkarni Samarth | Chief Executive Officer | May 20 | Option Exercise | 1.81 | 10,693 | 19,354 | 182,219 | May 21 04:35 PM | | Kulkarni Samarth | Chief Executive Officer | May 20 | Sale | 65.28 | 10,693 | 698,039 | 171,526 | May 21 04:35 PM | | Kulkarni Samarth | Chief Executive Officer | May 19 | Option Exercise | 1.81 | 4,307 | 7,796 | 175,833 | May 21 04:35 PM | | Novak Rodger | President | May 19 | Sale | 65.00 | 50,000 | 3,250,000 | 798,007 | May 21 04:37 PM | | Kulkarni Samarth | Chief Executive Officer | May 19 | Sale | 65.16 | 4,307 | 280,644 | 171,526 | May 21 04:35 PM | | Klein Lawrence Otto | CBO & COO | May 11 | Option Exercise | 5.86 | 25,000 | 146,500 | 45,000 | May 13 04:38 PM | | Klein Lawrence Otto | CBO & COO | May 11 | Sale | 60.40 | 25,000 | 1,509,971 | 20,000 | May 13 04:38 PM | | Kulkarni Samarth | Chief Executive Officer | Dec 16 | Option Exercise | 1.81 | 8,000 | 14,480 | 172,320 | Dec 18 04:05 PM | | Novak Rodger | President | Nov 19 | Option Exercise | 14.43 | 33,618 | 485,108 | 33,618 | Nov 21 04:09 PM | | CAGNONI PABLO J | Director | Nov 19 | Option Exercise | 5.59 | 7,500 | 41,925 | 7,500 | Nov 21 04:07 PM | | Novak Rodger | President | Nov 19 | Sale | 70.00 | 33,618 | 2,353,260 | 0 | Nov 21 04:09 PM | | CAGNONI PABLO J | Director | Nov 19 | Sale | 62.00 | 7,500 | 465,000 | 0 | Nov 21 04:07 PM | | Bolzon Bradley J PhD | Director | Nov 19 | Sale | 67.41 | 28,255 | 1,904,783 | 596,741 | Nov 21 07:53 PM | | Bolzon Bradley J PhD | Director | Nov 19 | Sale | 67.41 | 13,745 | 926,605 | 0 | Nov 21 07:53 PM | | CAGNONI PABLO J | Director | Nov 12 | Option Exercise | 5.59 | 7,500 | 41,925 | 7,500 | Nov 13 04:30 PM | | CAGNONI PABLO J | Director | Nov 12 | Sale | 55.00 | 7,500 | 412,500 | 0 | Nov 13 04:30 PM | | CAGNONI PABLO J | Director | Oct 30 | Option Exercise | 5.59 | 7,500 | 41,925 | 7,500 | Nov 01 06:35 PM | | CAGNONI PABLO J | Director | Oct 30 | Sale | 52.00 | 7,500 | 390,000 | 0 | Nov 01 06:35 PM | | Bolzon Bradley J PhD | Director | Oct 30 | Sale | 51.89 | 21,000 | 1,089,675 | 13,745 | Nov 01 06:34 PM |
|
